CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.
A leader from Medicines for Europe will share with CPhI Worldwide attendees a look at medicine production and offer solutions for elevating the industry.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
The cloud software firm’s Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.
An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.
During OSP’s November 17 online event, a group of experts will offer insights, advice, and examples of solutions that put patients at the center of studies.
The respiratory care specialist shares perspective on issues faced by respiratory studies, and how to overcome such obstacles to get therapies to market.
According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.
The advocacy group is joining with the Rare Disease Diversity Coalition on an initiative to identify and overcome challenges faced by minority patients.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
The Distributed Pharmaceutical Analysis Lab and the blockchain-based platform provider will work to prevent fake and low-quality drugs from circulating.
This month’s list of partnerships, manufacturing facilities, new technologies and other items includes AstraZeneca, Charles River, Veeva, and other firms.
With the launch of its Trialbee Honey technology, the company aims to bring together recruitment information from different sources for sweeter results.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
To fully reap the benefits of tech advances, a company leader advises, a life-sciences firm must embrace change and connection throughout the operation.
RSG Arrive is intended to increase clinical trial participation by offering ground transport, plane rides, hotels, visa procurement, and other services.
A leader from the drug development and manufacturing firm talks about the ways in which advanced digital tools stand to revolutionize the pharma field.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
A leader from the pharmaceutical firm talks about some of the most impactful technologies and shares a number of notable advancements made by the company.
The US agency plans to use the software firm’s Lighthouse technology to improve understanding of COVID-19 and other conditions in long-term care facilities.
The AI technology firm and pharma services company are joining to help one of the country’s leading pharmaceutical firms develop a promising drug candidate.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
According to two leaders from the healthcare tech firm, improving the way healthcare data is collected, stored, and used can contribute to improved care.
The patient-centric platform firm is gathering representatives from different corners of the industry to work on solutions to drive progress and innovation.
Organizers of the drug delivery and packaging event have shared an industry report that reveals what is likely to push innovation forward in the future.
The HIV treatment specialist has sent an application to the agency for tolutegravir, a single-tablet treatment indicated for children living with the virus.
An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.
This month’s news on appointments, expansions, acquisitions and other events includes Nanoform, Elligo Health Research, Curavit, and other organizations.
A representative from the school explains how tools like artificial intelligence and natural language processing can help elevate personalized medicine.
An expert from the CRO explains the evolution of data technologies put to use in clinical studies and offers advice on how to best make them work in trials.
According to the CEO of patient recruitment specialist SubjectWell, keeping up with the specialized needs of virtual studies calls for innovative thinking.
Leaders from ArisGlobal and Eversana explain the benefits of carefully selecting a research partner with a robust set of capabilities to see a project through.
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
A study by Charles River finds patients believe the overall quality of healthcare would increase if stakeholders across the life sciences collaborated more.
A leader from Swift Medical describes the company’s skin and wound management technology, and how their tech empowers patient capture of vital information.
The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
Conducted by patient services specialist Greenphire, the survey checks in with contract research organizations and shows how they are approaching obstacles.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
The protease inhibitor PF-07321332 (co-administered with ritonavir) is designed for patients exposed to (or showing the first signs of) the COVID-19 virus.
